FDA Approval and Comparison of Darolutamide in Prostate Cancer Treatment

This chapter discusses the FDA's approval of darolutamide for non-metastatic castrate-resistant prostate cancer, comparing it with enzalutamide and apalutamide. It covers clinical efficacy, dosing regimens, side effects, and the molecular characteristics of these treatments.